V ascular endothelial growth factor (VEGF)-A plays a central role in the growth and metastasis of solid tumors (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Through alternative splicing of RNA, human VEGF exists as at least four isoforms of 121, 165, 189, or 206 aa (11) (12) (13) (14) . The lowest molecular weight isoform, designated VEGF 121, is a nonheparan sulfate-binding isoform that exists in solution as a disulfide-linked homodimer.
The angiogenic actions of VEGF are mediated through two related receptor tyrosine kinases, kinase domain receptor (KDR) and FLT-1 in the human, and Flk-1 and Flt-1 in the mouse. Both are largely restricted to vascular endothelial cells (15) (16) (17) (18) . KDR͞ Flk-1 and FLT-1 receptors are overexpressed on the endothelium of tumor vasculature (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . In contrast, these receptors are almost undetectable in the vascular endothelium of adjacent normal tissues (18) . The receptors for VEGF thus seem to be excellent targets for the development of therapeutic agents that inhibit tumor growth and metastatic spread through inhibition of tumor neovascularization. To this end, VEGF 121 would be an appropriate carrier to deliver a toxic agent selectively to tumor vascular endothelium.
The recombinant toxin gelonin (rGel) is a single chain Nglycosidase similar in its action to ricin A chain (25) (26) (27) (28) . Immunotoxins and fusion constructs containing rGel specifically kill tumor cells in vitro and in vivo (ref. 29 and M.G.R., L.C., C. R. Parach, and J.W.M., unpublished work) and have antitumor activity in mice. Gelonin does not seem to generate capillary leak syndrome (31) , which limits use of other toxins.
Molecular engineering enabled the synthesis of novel chimeric molecules having therapeutic potential (32, 33) . Chimeric fusion constructs targeting the IL-2 receptor, the EGF receptor, and other growth factor͞cytokine receptors have been described (34, 35) . Studies by Ramakrishnan et al. (36) showed that a chemical conjugate of VEGF and truncated diphtheria toxin has impressive cytotoxic activity on cell lines expressing receptors for VEGF. Further studies with VEGF͞DT fusion constructs demonstrated selective toxicity to Caprice's sarcoma cells and dividing endothelial cells in vitro and in vivo (37) .
CCCGCCTCGGCTTGTC-3Ј); Gel Nterm, (5Ј-GGTGGCG-GTGGCTCCGGTCTAGACACCGTGAGC-3Ј); Gel Cterm, (5Ј-A AGGCTCGTGTCGACCTCGAGTCAT TA AGCT T-TAGGATCTTTATC-3Ј). A G 4 S linker was incorporated between the VEGF 121 and the rGel sequences. Purified PCR products were digested with the restriction enzymes BspHI and XhoI and ligated into the pET-32a. The constructs were transformed into Escherichia coli strain AD494 (DE3) pLys S for expression of the fusion protein.
Protein Expression in E. coli. Bacterial colonies transformed with the plasmid carrying the VEGF 121 ͞rGel insert were cultured in LB growth medium (Sigma) containing 200 g͞ml ampicillin, 70 g͞ml chloramphenicol, and 15 g͞ml kanamycin at 37°C overnight in a shaker bath at 240 rpm. The cultures then were diluted 1:20 with fresh LB medium with antibiotics and grown to early log phase (A 600 ϭ 0.6) at 37°C. Thereafter, the cultures were diluted 1:1 with fresh LB medium plus antibiotics; protein synthesis was induced at 23°C by the addition of 0.1 mM isopropyl ␤-Dthiogalactoside (IPTG) overnight. The cells were collected by centrifugation, resuspended in 10 mM Tris⅐HCl (pH 8.0), and frozen.
Protein Purification. Frozen bacterial cells were thawed, sonicated (5ϫ for 10 sec each), and then lysed further by the addition of 1 mg͞ml lysozyme in 10 mM Tris⅐HCl (pH 8.0) for 30 min at 4°C. The bacterial lysates were ultracentrifuged at 60,000 ϫ g for 45 min at 4°C, adjusted to 40 mM Tris⅐HCl (pH 8.0), filtered (0.22 m filter), and then loaded at room temperature onto a Talon-containing column. The column was washed with 40 mM Tris⅐HCl (pH 8.0) and 500 mM NaCl containing 5 mM imidazole and eluted with 100 mM imidazole. Protein-containing fractions were dialyzed into 20 mM Tris⅐HCl (pH 7.4) and 50 mM NaCl. The fusion protein was digested for 4 h at room temperature with recombinant enterokinase (20 units͞mg of fusion protein) in the presence of 2 mM CaCl 2 to remove the hexa-histidine tag and then dialyzed into 20 mM Tris⅐HCl (pH 8.0)͞50 mM NaCl. The samples were filter-sterilized before further use and stored at 4°C.
Anti-VEGF and Anti-rGel Western Blot Analysis. Protein samples were analyzed by SDS͞15% PAGE under reducing conditions. The gel was electrophoretically transferred to nitrocellulose overnight at 4°C in transfer buffer (25 mM Tris⅐HCl, pH 7.6͞190 mM glycine͞ 20% HPLC-grade methanol). The membranes were blocked by the addition of 5% BSA in Western blocking buffer [Tris-buffered saline (0.05 M Tris, 0.15 M NaCl) (TBS)͞0.5% Tween-20] and then incubated for 1 h with rabbit anti-gelonin polyclonal antibody (2 g͞ml in TBS͞Tween) or mouse anti-VEGF monoclonal antibody 2C3 (2 g͞ml in TBS͞Tween). The membrane then was incubated with goat-anti-rabbit IgG horseradish peroxidase (HRP) or goatanti-mouse IgG-HRP (1: 5,000 dilution in TBS͞Tween). Then, the membrane was developed with the Amersham Pharmacia enhanced chemiluminescence (ECL) detection system and exposed to x-ray film.
Rabbit Reticulocyte Lysate Assay. The functional activity of rGel and VEGF 121 ͞rGel were assayed by using a cell-free protein translation inhibition assay kit from Amersham Pharmacia as described by the manufacturer. Log-phase PAE͞KDR cells and PAE͞FLT-1 cells in F-12 medium [10% (vol͞vol) FBS] were diluted to 3,000 cells per 200 l. Aliquots (200 l) were added to 96-well flat-bottomed tissue culture plates and incubated at 37°C for 24 h in 5% CO 2 . Purified VEGF 121 ͞rGel or rGel were diluted in culture medium, added to the plate, and incubated for 72 h. Adherent cells were quantified by using the crystal violet staining method described above.
Kinase Activity of KDR in PAE͞KDR Cells Exposed to VEGF121͞rGel or VEGF121. PAE͞KDR cells were incubated overnight in F-12 culture medium and then incubated at 37°C for 5 min with 100 M Na 3 VO 4 . VEGF or VEGF 121 ͞rGel then were added and, at various times, cells were lysed by the addition of a lysis buffer [50 mM Hepes, pH 7.4͞150 mM NaCl͞1 mM EGTA͞10 mM sodium pyrophosphate͞1.5 mM MgCl 2 ͞100 mM NaF͞10% (vol͞vol) glycerol͞1% Triton X-100]. Cell lysates were centrifuged (16,000 ϫ g), the supernatants were removed, and their protein concentrations were determined. Lysate supernatants were incubated with 9 g anti-phosphotyrosine monoclonal antibody (Santa Cruz Biotechnology) for 2 h at 4°C and then precipitated by the addition of Protein A Sepharose beads for 2 h at 4°C. Beads were washed and mixed with SDS sample buffer, heated for 5 min at 100°C, centrifuged, analyzed by SDS͞10% PAGE, and then transferred to nitrocellulose filters. The membranes were blocked with 5% nonfat dry milk and incubated with rabbit polyclonal anti-KDR antibody (1:250; Santa Cruz Biotechnology) for 1 h at room temperature. The membranes then were washed, incubated with a peroxidase-linked goat anti-rabbit antibody (1:2,000) for 1 h at room temperature, and then enhanced chemiluminescence reagent (Amersham Pharmacia) was used to visualize the immunoreactive bands.
Immunohistochemical Analysis of VEGF121͞rGel in Tumor Xenografts.
Mice (three mice per group) bearing PC-3 tumors were injected intravenously with 50 g of the fusion protein gelonin. The mean tumor volume per group was 260 mm 3 . Thirty minutes later, mice were killed, exsanguinated, and all major tissues were snapfrozen. Frozen sections were cut and double stained with pan-endothelial marker MECA-32 (5 g͞ml) followed by detection of the localized fusion protein by using rabbit antigelonin antibody (10 g͞ml). MECA-32 rat IgG was visualized with goat anti-rat IgG conjugated to FITC (red fluorescence). Anti-gelonin antibody was detected with goat anti-rabbit IgG conjugated to Cy-3 (green fluorescence). Colocalization of both markers was indicated by a yellow color. Anti-gelonin antibody had no reactivity with tissue sections from mice injected with saline or VEGF 121 . To determine the percentage of vessels with localized fusion protein, the number of vessels stained with MECA-32 (red), gelonin (green), or both (yellow) were counted at a magnification of ϫ200 in at least 10 fields per section. Two slides from each mouse were analyzed, and the average percentage of positive vessels was calculated.
In Vivo Therapy in Xenograft Models. Human melanoma. Female nu͞nu mice were divided into groups of five mice each. Log-phase A-375M human melanoma cells were injected s.c. (5 ϫ 10 6 cells per mouse) into the right flank. After the tumors had become established (Ϸ50 mm 3 ), the mice were injected with VEGF 121 ͞rGel through a tail vein five times over an 11 day period. The total dose of VEGF͞rGel was 17 or 25 mg͞kg. Other mice received rGel alone at a dose totaling 10 mg͞kg. Mice were killed by cervical dislocation after the 40th day of tumor measurement.
Human prostate cancer. Male nude mice weighing Ϸ20 g were divided into groups of five mice each. Log-phase PC-3 human prostate tumor cells were injected s.c. (5 ϫ 10 6 cells per mouse) in the right flank. The mice were injected with VEGF 121 ͞rGel through a tail vein every 2-3 days for 11 days. The total dose of VEGF 121 ͞rGel was 20 mg͞kg. Other mice received rGel alone at a dose totaling 10 mg͞kg. Tumor volume was calculated according to the formula: volume ϭ L ϫ W ϫ H, where L ϭ length, W ϭ width, H ϭ height.
A histological study was performed in which groups of three mice bearing PC-3 tumors were given i.v. injections of either saline or VEGF 121 ͞rGel (2.5 mg͞kg). Forty-eight hours later, the mice were killed, and organs and tumors were removed and fixed in formalin. Paraffin sections were prepared, stained with hematoxylin and eosin, and examined by light microscopy.
Results

Plasmid Construction, Bacterial Expression, and Purification of Fusion
Protein. The cDNA encoding human VEGF 121, a G 4 S flexible tether, and rGel were joined with a PCR-based method (see Fig.  6 , which is published as supporting information on the PNAS web site, www.pnas.org). The construct was ligated into the pET-32a vector, transformed into E. coli strain AD494(DE3) plys S, and the fusion protein was expressed and purified from bacterial supernatant. Fig. 7 , which is published as supporting information on the PNAS web site, shows the SDS͞PAGE analysis of protein expression after induction with IPTG. The lane containing the induced culture shows a new protein at 62 kDa, which is the expected molecular weight for the fusion protein plus the 21 kDa purification tag. This material was purified by binding and elution from immobilized metal affinity (IMAC) resin. Cleavage with recombinant enterokinase removed the tag resulting in a 42-kDa protein under reducing conditions (Fig. 7) . The construct migrated as a homodimer at 84 kDa under nonreducing conditions. The fusion construct was immunoreactive with antibodies to both VEGF and rGel (Fig. 7) . One liter of induced bacterial culture initially contained Ϸ2,000 g of soluble fusion construct. Initial IMAC purification resulted in 750 g of VEGF 121 ͞rGel product (yield 37.5%), and digestion with recombinant enterokinase generated 400 g of target protein (yield 20%). Subsequent purification yielded 230 g of VEGF 121 ͞rGel final product (11.5% overall yield).
Biological Activity of the rGel Component. The ability of VEGF 121 ͞ rGel and rGel to inhibit translation in a cell-free system was determined by using a rabbit reticulocyte translation assay. The purified VEGF 121 ͞rGel and rGel had IC 50 values of Ϸ47 and 185 pM, respectively, showing that fusion of rGel and VEGF 121 did not reduce the activity of the toxin component.
Binding of VEGF121͞rGel to Soluble Flk-1 Receptor. The fusion protein was tested for its ability to bind to the Flk-1 receptor by ELISA. Fig.  8 , which is published as supporting information on the PNAS web site, shows that VEGF 121 ͞rGel and native human VEGF 121 bind equally well to Flk-1 at all concentrations, indicating that the VEGF component of the fusion protein is fully capable of binding to Flk-1. The specificity of binding of VEGF 121 ͞rGel to Flk-1 was confirmed by using a 10-fold molar excess of free VEGF 121.
VEGF121͞rGel and VEGF121-Induced Phosphorylation of KDR. PAE͞ KDR cells overexpressing the KDR were incubated with VEGF 121 ͞rGel fusion construct or VEGF 121 itself, and Western analysis of phospho-tyrosine content of the receptors was measured at various later time points. As shown in Fig. 9 , which is published as supporting information on the PNAS web site, addition of VEGF 121 ͞rGel or VEGF 121 increased phosphotyrosine content. There were two phases of phosphorylation; an early phase (1-10 min) and a later phase (4-8 h). The time course of induction of KDR phosphorylation was the same for VEGF 121 ͞rGel and VEGF 121 . Phosphorylation of FLT-1 in PAE͞FLT-1 cells treated with either VEGF 121 ͞rGel or VEGF 121 was not observed, as expected from the weaker signaling of FLT-1 compared with KDR observed by others (40) .
Cytotoxicity of VEGF121͞rGel to Endothelial Cells in Vitro. VEGF 121 ͞ rGel was specifically toxic to KDR͞Flk-1 expressing endothelial cells in vitro ( Fig. 1 and Table 1 ). The IC 50 values for VEGF 121 ͞rGel on log-phase PAE͞KDR, ABAE, and bEnd.3 cells, which express 1-3 ϫ 10 5 KDR͞Flk-1 receptors per cell, was 0.06 to 1 nM. Cells expressing FLT-1 and having low endogenous expression of KDR (PAE͞FLT-1, HUVEC) were several hundred-fold more resistant to VEGF 121 ͞rGel than were the KDR͞Flk-1 expressing cells. Thus, FLT-1 appears not to mediate cytotoxicity of VEGF 121 ͞rGel, in agreement with earlier reports (41) . The ratio of IC 50 values of rGel to VEGF 121 ͞rGel was calculated for each cell type. This ratio (the targeting index) represents the ability of the VEGF component of the fusion construct to mediate the delivery of the toxin to the endothelial cell surface and into the intracellular ribosomal compartment. As summarized in Table 1 , bEnd.3 and ABAE cells were, respectively, 100-fold and 9-fold more sensitive to the fusion construct than they were to free rGel.
Selective Cytotoxicity of VEGF121͞rGel for Dividing PAE͞KDR Cells.
VEGF 121 ͞rGel was 60-fold more toxic to PAE͞KDR cells in log-phase growth than it was to PAE͞KDR cells that had been grown to confluence and rested (Table 1 ). This effect was not caused by differences in KDR expression, because the cells expressed the same number of KDR receptors per cell in both phases of growth. The log-phase PAE͞KDR cells also were more sensitive to rGel itself than were the confluent cells, suggesting that the quiescence of confluent cells impacts their sensitivity to both targeted and nontargeted rGel. It is possible that the rate or route of entry of both VEGF 121 ͞rGel and rGel is different for dividing and nondividing cells. (Fig. 2) . Treatment of the mice with VEGF 121 ͞ rGel strongly retarded tumor growth. At high doses of VEGF 121 ͞ rGel totaling 25 mg͞kg, tumor growth was completely prevented, but all mice died from drug toxicity on day 19. At lower doses totaling 17 mg͞kg, all mice survived. Tumor growth was completely prevented throughout the 14-day course of treatment, but thereafter, tumor regrowth slowly recurred. Compared with controls, mice treated with VEGF 121 ͞rGel at doses totaling 17 mg͞kg showed a 6-fold decrease in tumor volume (1,200 mm 
Inhibition of Tumor Growth in Vivo by
Localization of VEGF121͞rGel to Vascular Endothelium in PC-3 Tumor
Xenografts. Mice bearing s.c. PC-3 tumors were given one i.v. dose of VEGF 121 ͞rGel (2.5 mg͞kg) or free gelonin (1 mg͞kg) and, 30 min later, the mice were exsanguinated. Frozen sections of tumor and normal organs were examined immunohistochemically. VEGF 121 ͞rGel was detected primarily on vascular endothelium of PC-3 tumors (Fig. 4) . On average, 62% of vessels positive for MECA 32 also were positive for VEGF 121 ͞rGel, as detected by using anti-gelonin antibody. In tumor regions of increased vascularity (''hot spots''), approximately 90% of tumor vessels had bound VEGF 121 ͞rGel. Vessels in normal organs were unstained, with the exception of the kidney, where weak and diffuse staining was detected in the glomeruli. Free gelonin did not localize to tumor or normal vessels in any of the mice. These results indicate that VEGF 121 ͞rGel localized specifically to tumor vessels after i.v. injection.
Destruction and Thrombosis of Tumor Vessels by VEGF121͞rGel. Mice bearing s.c. PC-3 tumors were given one i.v. dose of VEGF 121 ͞rGel (2.5 mg͞kg) or saline. The mice were killed 48 h later, and the tumors and various organs were removed. Paraffin sections were prepared and stained with hematoxylin and eosin. The tumors from VEGF 121 ͞rGel recipients (Fig. 5 ) displayed damaged vascular endothelium, thrombosis of vessels, and extravasation of RBC components into the tumor interstitium. Normal tissues had un- damaged vasculature. Treatment of mice with saline had no effect on tumor or normal tissues. As assessed by image analysis, necrotic areas of the tumor increased from Ϸ4% in saline-treated mice to Ͼ12% after treatment with the fusion construct.
Discussion
The expression of VEGF and its receptors has been closely linked to tumor vascularity, metastasis, and progression (42) (43) (44) (45) . Several groups have developed antiangiogenic drugs that block kinase activity of the VEGF receptors (46) or monoclonal antibodies that block VEGF-receptor interactions (47, 48) .
The current study demonstrates a chimeric fusion construct containing VEGF and the plant toxin gelonin. VEGF 121 ͞rGel was found to be selectively toxic to dividing endothelial cells overexpressing the KDR͞Flk-1 receptor. Nondividing (confluent) endothelial cells were almost 60-fold more resistant than were dividing cells to the fusion construct and also were more resistant to free rGel (Table 1) . These findings accord with those of previous studies by Wild et al. (32) , who showed that conjugates of VEGF and DT were highly toxic to log-phase cells but were not toxic to confluent endothelial cells. The greater sensitivity of dividing endothelial cells to VEGF-toxin constructs may be because of differences in intracellular routing or catabolism of the construct as observed with other targeted therapeutic agents (49) .
Cytotoxicity studies demonstrated that expression of the KDR͞Flk-1 receptor is needed for VEGF 121 ͞rGel to be cytotoxic. Cells overexpressing KDR͞Flk-1 (Ͼ1 ϫ 10 5 sites per cell) were highly sensitive to the VEGF 121 ͞rGel fusion construct, whereas cells expressing fewer than 0.4 ϫ 10 5 sites per cell were no more sensitive to the fusion toxin than they were to free rGel. Again, the requirement to surpass a threshold level of KDR͞ Flk-1 for cytotoxicity may contribute to the safety of VEGF 121 ͞ rGel. In normal organs, including the kidney glomerulus and pulmonary vascular endothelium (19) , the level of KDR͞Flk-1 may be below that needed to cause toxicity. The number of receptors for VEGF on endothelial cells in the vasculature of normal organs has been reported by Brown et al. (19, 50) to be significantly lower than on tumor vasculature. Indeed, we could not detect binding of VEGF 121 ͞rGel to normal vascular endothelium in organs other than the kidney, where weak binding was observed. Furthermore, no damage to vascular endothelium was observed in normal organs, including the kidney.
Other gelonin-based-targeted therapeutics also have been observed to become toxic to cells only when a certain threshold level of binding is surpassed. In a recent study of immunotoxins directed against the c-erb-2͞HER2͞neu oncogene product, immunotoxins were not cytotoxic to tumor cells expressing less than about 1 ϫ 10 6 HER2͞neu sites per cell (29) . The lack of sensitivity of cells having low levels of receptors is presumably because the cells internalize too little of the toxin or traffic it to compartments that do not permit translocation of the toxin to the ribosomal compartment.
Our study also demonstrates that the presence of FLT-1, even at high levels, does not seem to mediate cellular toxicity of the VEGF 121 ͞rGel fusion toxin. Although VEGF binds to the FLT-1 receptor (51), the current study (40, 52) has been unable to demonstrate receptor phosphorylation as a result of ligand binding. Dougher and Terman (53) suggested that receptor phosphorylation may be required for KDR signaling and internalization. If so, the receptor-fusion-toxin complex may not internalize efficiently enough after binding to FLT-1 for the fusion protein to be routed to an intracellular compartment from Fig. 3 . Inhibition of human prostate carcinoma growth in mice by VEGF͞ rGel. Groups of nude mice bearing PC-3 tumors were treated intravenously with saline, rGel, or the VEGF 121͞rGel fusion construct (20 mg͞kg total dose) every 2-3 days for 11 days. Administration of rGel (10 mg͞kg) had no effect on tumor growth. In contrast, treatment with the fusion construct completely inhibited tumor growth for 26 days and resulted in a 7-fold reduction in tumor volume compared with saline-treated or rGel-treated controls. Nude mice bearing human prostate PC-3 tumors were injected i.v. with VEGF 121͞rGel or rGel (2.5 mg͞kg). Thirty minutes after administration, tissues were removed and snap frozen. Sections were stained with immunofluorescent reagents to detect murine blood vessels (MECA-32, red) and with antirGel (green). Vessels stained with both reagents appear yellow. VEGF͞rGel localized to tumor vessels, whereas rGel did not. Vessels in all normal organs other than the kidney (glomerulus) were unstained by VEGF͞rGel. 5 mg͞kg) . Forty-eight hours after administration, tissues were snap-frozen, sectioned, and stained with hematoxylin and eosin. As shown in this representative image, tumors from mice treated with the fusion construct had damaged vascular endothelium. Clots were visible in the larger vessels of the tumors, and erythrocytes were visible in the tumor interstitium, indicating a loss of vascular integrity. In contrast, histological damage was not visible in any normal organs, including the kidneys, of treated mice.
which the toxin can escape to the cytosol. The relative contributions of the FLT-1 and KDR receptors to the biological effects of VEGF examined by using a monoclonal antibody that blocks the interaction of VEGF with KDR͞Flk-1 but not FLT-1 demonstrate that KDR͞Flk-1 is the major receptor determining the vascular permeability-inducing and angiogenic effects of VEGF in tumors (48) .
Although VEGF 121 ͞rGel induces phosphorylation of KDR receptor, we observed no growth-stimulatory effects of the fusion toxin on VEGF receptor-expressing cells. These findings are in keeping with studies of other fusion toxins such as IL-2͞DT that initially stimulate target cells in a manner similar to that of IL-2 itself, but ultimately kill the target cells through the actions of the internalized toxin (54) .
The antitumor effects of the VEGF 121 ͞rGel fusion construct against both melanoma and human prostate carcinoma xenografts was impressive in magnitude and prolonged. A-375M and PC-3 cells in culture were resistant to the fusion construct in vitro, despite the reported presence of KDR on the melanoma (but not on PC-3) cells (55) . Therefore, the antitumor effects observed in vivo appear not to be caused by direct cytotoxic effects of VEGF121͞rGel on the tumor cells themselves. The antitumor effect seems to be exerted indirectly on the tumor cells through specific damage to tumor vasculature. The VEGF 121 fusion toxin localized to tumor blood vessels after i.v. administration. Vascular damage and thrombosis of tumor blood vessels were observed within 48 h of administration of VEGF 121 ͞rGel to PC-3 mice, consistent with the primary action of the construct being exerted on tumor vascular endothelium.
In summary, our results indicate that selective destruction of tumor vasculature can be achieved with VEGF 121 ͞rGel in mice, giving impressive antitumor effects. Gross morphological toxicity to the normal organs was not visible in animals treated with a therapeutic dose. These studies suggest that VEGF 121 ͞rGel has potential as an antitumor agent for treating cancer patients.
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